GEMINI ACS 1

This is a randomized, double-blind, double-dummy, active-controlled, parallel-group, multicenter study to compare the safety of Rivaroxaban versus Acetylsalicylic Acid in addition to either Clopidogrel or Ticagrelor therapy in subjects with acute coronary syndrome.

Awarded By

  • Janssen Research & Development

Contributors

Amount

  • $2,426,062.00

Start/End

  • 2016 - 2018